Anaplastic astrocytoma and non-1p/19q co-deleted anaplastic oligoastrocytoma: Long-term survival, employment, and performance status of survivors Journal Article
| Authors: | Pentsova, E. I.; Reiner, A. S.; Panageas, K. S.; DeAngelis, L. M. |
| Article Title: | Anaplastic astrocytoma and non-1p/19q co-deleted anaplastic oligoastrocytoma: Long-term survival, employment, and performance status of survivors |
| Abstract: | Background. Despite optimal treatment for patients with anaplastic gliomas, median survival is 2 to 5 years, but some young adults survive longer. We sought to evaluate the functional and employment status of long-term survivors (5 years or more) diagnosed with anaplastic astrocytoma or non-1p/19q co-deleted anaplastic oligoastrocytoma. Methods. We retrospectively identified patients with a diagnosis of anaplastic glioma at Memorial Sloan Kettering Cancer Center from 1999 to 2005. We reviewed demographics, pathology, 1p/19q status, survival, and treatment. Overall survival was estimated by the Kaplan-Meier method. Results. There were 195 patients; 167 with anaplastic astrocytoma and 28 with anaplastic oligoastrocytoma. All patients were observed either to death or last follow-up. Sixty-four patients (33%) were identified as long-term survivors; 58% of these were men. The median age of the long-term survivors was 39 years and the median Karnofsky Performance Score was 100 at diagnosis. Thirteen patients underwent stereotactic biopsy, 7 had a gross total resection, and 44 a subtotal resection. Fifty-four patients completed radiation therapy as initial treatment; 54 received chemotherapy. Five years following diagnosis, median KPS was 90 and 55% of longterm survivors were employed and remained fully functional. Conclusions. One-third of patients with non-co-deleted anaplastic glioma were long-term survivors, and more than one-half of longterm survivors resumed their prior level of employment and activity. However, a significant proportion could not return to normal function. These findings have serious implications for the social and financial status of these predominantly young adult survivors. © The Author(s) 2015. |
| Keywords: | cancer chemotherapy; cancer surgery; overall survival; cancer radiotherapy; temozolomide; follow up; carboplatin; vincristine; retrospective study; carmustine; lomustine; procarbazine; survivor; karnofsky performance status; glioblastoma; scoring system; carboxymethylcellulose polycytidylic polyinosinic acid polylysine; cognitive defect; kaplan meier method; employment status; chromosome deletion; astrocytoma; stereotactic biopsy; chromosome 1p; chromosome 19q; employment; anaplastic oligoastrocytoma; anaplastic astrocytoma; priority journal; article |
| Journal Title: | Neuro-Oncology Practice |
| Volume: | 3 |
| Issue: | 2 |
| ISSN: | 2054-2577 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-06-01 |
| Start Page: | 71 |
| End Page: | 76 |
| Language: | English |
| DOI: | 10.1093/nop/npv043 |
| PROVIDER: | scopus |
| PMCID: | PMC6668265 |
| PUBMED: | 31386086 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
252Reiner -
576De Angelis -
132Pentsova -
519Panageas
Related MSK Work